187 related articles for article (PubMed ID: 36166850)
1. Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population.
Vic S; Lemoine J; Armand P; Lemonnier F; Houot R
Eur J Cancer; 2022 Nov; 175():246-253. PubMed ID: 36166850
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
[TBL] [Abstract][Full Text] [Related]
3. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
4. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
Westin J; Sehn LH
Blood; 2022 May; 139(18):2737-2746. PubMed ID: 35240677
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
[TBL] [Abstract][Full Text] [Related]
6. CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A; Kirkwood AA; Roddie C; Menne T; Tholouli E; Bloor A; Besley C; Chaganti S; Osborne W; Norman J; Gibb A; Sharplin K; Cuadrado M; Correia de Farias M; Cheok K; Neill L; Latif AL; González Arias C; Uttenthal B; Jones C; Johnson R; McMillan A; Sanderson R; Townsend W
Br J Haematol; 2023 Jul; 202(1):65-73. PubMed ID: 37082780
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
9. Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
Puckrin R; Stewart DA; Shafey M
Transplant Cell Ther; 2022 Apr; 28(4):218.e1-218.e4. PubMed ID: 35123117
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
11. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma.
Ring A; Grob B; Aerts E; Ritter K; Volbracht J; Schär B; Greiling M; Müller AMS
Ann Hematol; 2022 Aug; 101(8):1755-1767. PubMed ID: 35759026
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
Harrysson S; Eloranta S; Ekberg S; Enblad G; El-Galaly TC; Sander B; Sonnevi K; Andersson PO; Jerkeman M; Smedby KE
Br J Haematol; 2022 Jul; 198(2):267-277. PubMed ID: 35468219
[TBL] [Abstract][Full Text] [Related]
14. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract][Full Text] [Related]
15. CAR-T in B-Cell Lymphomas: The Past, Present, and Future.
Al-Juhaishi T; Ahmed S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e261-e268. PubMed ID: 34782260
[TBL] [Abstract][Full Text] [Related]
16. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
Li C; Zhang Y; Zhang C; Chen J; Lou X; Chen X; Kang L; Xu N; Li M; Tan J; Sun X; Zhou J; Yang Z; Zong X; Wang P; Xu T; Qu C; Huang H; Jin Z; Yu L; Wu D
JCI Insight; 2019 Jul; 5(17):. PubMed ID: 31335321
[TBL] [Abstract][Full Text] [Related]
17. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review.
Neuendorff NR; Khan A; Ullrich F; Yates S; Devarakonda S; Lin RJ; von Tresckow B; Cordoba R; Artz A; Rosko AE
J Geriatr Oncol; 2024 Apr; 15(3):101734. PubMed ID: 38430810
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
Wang T; Gao L; Wang Y; Zhu W; Xu L; Wang Y; Yue W; Tang G; Chen L; Chen J; Zhang W; Yu X; Feng D; Yang J
Immunotherapy; 2020 Sep; 12(13):997-1006. PubMed ID: 32752910
[No Abstract] [Full Text] [Related]
19. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
